CR20120094A - Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo - Google Patents
Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismoInfo
- Publication number
- CR20120094A CR20120094A CR20120094A CR20120094A CR20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A
- Authority
- CR
- Costa Rica
- Prior art keywords
- same
- preparation methods
- new antibiotic
- mimetic antibody
- mimetic
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención pertenece al campo de la biología y la medicina, y especialmente se relaciona a un antibiótico novedoso que comprende un anticuerpo mimético, sus métodos de preparación y usos de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100921284A CN101633699B (zh) | 2009-09-02 | 2009-09-02 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120094A true CR20120094A (es) | 2012-06-05 |
Family
ID=41593050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120094A CR20120094A (es) | 2009-09-02 | 2012-02-23 | Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2474558B1 (es) |
CN (1) | CN101633699B (es) |
AP (1) | AP3302A (es) |
AU (1) | AU2010291640B2 (es) |
CR (1) | CR20120094A (es) |
DK (1) | DK2474558T3 (es) |
EA (1) | EA028912B1 (es) |
ES (1) | ES2538840T3 (es) |
HK (1) | HK1168113A1 (es) |
IL (1) | IL218435A (es) |
MY (1) | MY161926A (es) |
NZ (1) | NZ598593A (es) |
SG (1) | SG178503A1 (es) |
UA (1) | UA102325C2 (es) |
WO (1) | WO2011026447A1 (es) |
ZA (1) | ZA201201386B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633699B (zh) * | 2009-09-02 | 2012-02-15 | 畿晋庆堂国际生物技术有限公司 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
CN102101888B (zh) * | 2009-12-17 | 2013-03-20 | 畿晋庆三联(北京)生物技术有限公司 | 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法 |
CN102747041B (zh) | 2011-04-21 | 2014-07-16 | 畿晋庆三联(北京)生物技术有限公司 | 抗蓝藻重组抗体多肽及其基因与制备方法 |
CN103131724B (zh) * | 2011-11-25 | 2015-02-25 | 畿晋庆三联(北京)生物技术有限公司 | 一种高效表达工程菌重组蛋白的方法及应用 |
KR20140104475A (ko) * | 2011-12-08 | 2014-08-28 | 프로틴 디자인 랩, 리미티드 | 신규 항생제 제조방법 및 이 방법에 기초한 플랫폼 시스템 |
CN114369158B (zh) * | 2021-09-28 | 2024-04-19 | 北京亦科信息菌素研究院有限公司 | 一种抗新冠病毒的信息菌素及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330758C (zh) * | 2005-01-21 | 2007-08-08 | 四川大学 | 抗真菌多肽及其制备方法 |
CN100485038C (zh) * | 2005-09-13 | 2009-05-06 | 四川大学华西医院 | 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法 |
WO2007083175A1 (en) * | 2006-01-17 | 2007-07-26 | West China Hospital, Sichuan University | Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
CN101215568B (zh) * | 2008-01-18 | 2010-06-23 | 畿晋庆三联(北京)生物技术有限公司 | 抗炭疽多肽及其应用与制备方法 |
CN101633699B (zh) * | 2009-09-02 | 2012-02-15 | 畿晋庆堂国际生物技术有限公司 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
-
2009
- 2009-09-02 CN CN2009100921284A patent/CN101633699B/zh active Active
-
2010
- 2010-09-27 ES ES10813369.5T patent/ES2538840T3/es active Active
- 2010-09-27 AP AP2012006185A patent/AP3302A/xx active
- 2010-09-27 MY MYPI2012000747A patent/MY161926A/en unknown
- 2010-09-27 NZ NZ598593A patent/NZ598593A/xx not_active IP Right Cessation
- 2010-09-27 EP EP10813369.5A patent/EP2474558B1/en active Active
- 2010-09-27 WO PCT/CN2010/077351 patent/WO2011026447A1/zh active Application Filing
- 2010-09-27 AU AU2010291640A patent/AU2010291640B2/en not_active Ceased
- 2010-09-27 SG SG2012011532A patent/SG178503A1/en unknown
- 2010-09-27 UA UAA201202043A patent/UA102325C2/uk unknown
- 2010-09-27 EA EA201200417A patent/EA028912B1/ru not_active IP Right Cessation
- 2010-09-27 DK DK10813369.5T patent/DK2474558T3/en active
-
2012
- 2012-02-23 CR CR20120094A patent/CR20120094A/es unknown
- 2012-02-24 ZA ZA2012/01386A patent/ZA201201386B/en unknown
- 2012-03-01 IL IL218435A patent/IL218435A/en not_active IP Right Cessation
- 2012-09-10 HK HK12108839.4A patent/HK1168113A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA028912B1 (ru) | 2018-01-31 |
AU2010291640B2 (en) | 2013-02-07 |
IL218435A0 (en) | 2012-04-30 |
MY161926A (en) | 2017-05-15 |
HK1168113A1 (en) | 2012-12-21 |
NZ598593A (en) | 2013-07-26 |
WO2011026447A1 (zh) | 2011-03-10 |
UA102325C2 (uk) | 2013-06-25 |
SG178503A1 (en) | 2012-03-29 |
IL218435A (en) | 2016-04-21 |
AP3302A (en) | 2015-06-30 |
ES2538840T3 (es) | 2015-06-24 |
EP2474558B1 (en) | 2015-04-15 |
EA201200417A1 (ru) | 2012-07-30 |
EP2474558A1 (en) | 2012-07-11 |
DK2474558T3 (en) | 2015-06-15 |
AP2012006185A0 (en) | 2012-04-30 |
CN101633699A (zh) | 2010-01-27 |
EP2474558A4 (en) | 2013-03-27 |
CN101633699B (zh) | 2012-02-15 |
ZA201201386B (en) | 2013-08-28 |
AU2010291640A1 (en) | 2012-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20180175A (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
CL2017003356A1 (es) | Moduladores cot y métodos de uso de los mismos | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
CR20110576A (es) | Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos | |
CR20120215A (es) | Anticuerpos contra csf-1r humano y usos de los mismos | |
ECSP13012786A (es) | Anticuerpos anti-pcsk9 y métodos de uso | |
CR20120184A (es) | Anticuerpos monoclonales frente a progastrina y su usos | |
UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
UY34779A (es) | Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen | |
CR20120094A (es) | Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo | |
CO6551674A2 (es) | Anticuerpos anti-her3 y usos de los mismo | |
ECSP13012859A (es) | Anticuerpos del cea | |
CL2012000429A1 (es) | Uso de cepas de bifidobacterium longum para la elaboracion de una completa composicion que sirve para reducir los sintomas de alergias. | |
HN2012000263A (es) | Derivados n1-sulfonil-5-fluoropirimidinona | |
MX370199B (es) | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). | |
TR201909788T4 (tr) | C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri. | |
ECSP12011701A (es) | Anticuerpos anti-cdcp1 humanizados | |
CR20160147A (es) | Formulaciones de anticuerpos | |
BR112018011526A2 (pt) | compostos policíclicos como inibidores da tirosina quinase de bruton | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
ECSP12011653A (es) | Derivados de n1-acil-5-fluoropirimidinona | |
BR112015008389A2 (pt) | compostos úteis na síntese de compostos de benzamida | |
CR20140124A (es) | Metabolitos de transclomifeno y usos de los mismos |